Cargando…
MacuFix® versus Amsler grid for metamorphopsia categorization for macular diseases
PURPOSE: Macular diseases often lead to metamorphopsia, which is traditionally tested using the Amsler grid. This study evaluates a novel method for assessing metamorphopsia, based on the software AMD-A Metamorphopsia Detector, application MacuFix®. METHODS: In this observational study, the usabilit...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380298/ https://www.ncbi.nlm.nih.gov/pubmed/34420124 http://dx.doi.org/10.1007/s10792-021-02017-3 |
_version_ | 1783741170133762048 |
---|---|
author | Claessens, Daniela Ichhpujani, Parul Singh, Rohan Bir |
author_facet | Claessens, Daniela Ichhpujani, Parul Singh, Rohan Bir |
author_sort | Claessens, Daniela |
collection | PubMed |
description | PURPOSE: Macular diseases often lead to metamorphopsia, which is traditionally tested using the Amsler grid. This study evaluates a novel method for assessing metamorphopsia, based on the software AMD-A Metamorphopsia Detector, application MacuFix®. METHODS: In this observational study, the usability of a new smartphone-based testing method to assess metamorphopsia was evaluated in 45 patients experiencing metamorphopsia in at least one eye using the questionnaire “System Usability Score (SUS).” Additionally, the diagnostic adherence of self-monitoring with the Amsler grid was compared to self-monitoring with the novel software MacuFix®. RESULTS: The average score of the SUS questionnaire in this study was 76.7 ± 15.5, corresponding to the “good” score on the grading scale. The average interval between two home administered tests was significantly shorter (6 days) when the application was used as compared to using the Amsler grid (19 days). The odds ratio of the frequency of patients using the application to the patients using the home test was 4. CONCLUSION: MacuFix® application can help in effective home monitoring of macular function as high user satisfaction and increased testing frequency was observed in its use in patients with macular diseases. |
format | Online Article Text |
id | pubmed-8380298 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Netherlands |
record_format | MEDLINE/PubMed |
spelling | pubmed-83802982021-08-23 MacuFix® versus Amsler grid for metamorphopsia categorization for macular diseases Claessens, Daniela Ichhpujani, Parul Singh, Rohan Bir Int Ophthalmol Original Paper PURPOSE: Macular diseases often lead to metamorphopsia, which is traditionally tested using the Amsler grid. This study evaluates a novel method for assessing metamorphopsia, based on the software AMD-A Metamorphopsia Detector, application MacuFix®. METHODS: In this observational study, the usability of a new smartphone-based testing method to assess metamorphopsia was evaluated in 45 patients experiencing metamorphopsia in at least one eye using the questionnaire “System Usability Score (SUS).” Additionally, the diagnostic adherence of self-monitoring with the Amsler grid was compared to self-monitoring with the novel software MacuFix®. RESULTS: The average score of the SUS questionnaire in this study was 76.7 ± 15.5, corresponding to the “good” score on the grading scale. The average interval between two home administered tests was significantly shorter (6 days) when the application was used as compared to using the Amsler grid (19 days). The odds ratio of the frequency of patients using the application to the patients using the home test was 4. CONCLUSION: MacuFix® application can help in effective home monitoring of macular function as high user satisfaction and increased testing frequency was observed in its use in patients with macular diseases. Springer Netherlands 2021-08-22 2022 /pmc/articles/PMC8380298/ /pubmed/34420124 http://dx.doi.org/10.1007/s10792-021-02017-3 Text en © The Author(s), under exclusive licence to Springer Nature B.V. 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Original Paper Claessens, Daniela Ichhpujani, Parul Singh, Rohan Bir MacuFix® versus Amsler grid for metamorphopsia categorization for macular diseases |
title | MacuFix® versus Amsler grid for metamorphopsia categorization for macular diseases |
title_full | MacuFix® versus Amsler grid for metamorphopsia categorization for macular diseases |
title_fullStr | MacuFix® versus Amsler grid for metamorphopsia categorization for macular diseases |
title_full_unstemmed | MacuFix® versus Amsler grid for metamorphopsia categorization for macular diseases |
title_short | MacuFix® versus Amsler grid for metamorphopsia categorization for macular diseases |
title_sort | macufix® versus amsler grid for metamorphopsia categorization for macular diseases |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380298/ https://www.ncbi.nlm.nih.gov/pubmed/34420124 http://dx.doi.org/10.1007/s10792-021-02017-3 |
work_keys_str_mv | AT claessensdaniela macufixversusamslergridformetamorphopsiacategorizationformaculardiseases AT ichhpujaniparul macufixversusamslergridformetamorphopsiacategorizationformaculardiseases AT singhrohanbir macufixversusamslergridformetamorphopsiacategorizationformaculardiseases |